HOME ABOUT CONTACT PREVIOUS ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Intelligent Sensor Informs You to Change a Diaper via SMS       » University of Manchester & A*STAR ongoing partnership- Joint PhD programme       » Philippines Healthcare & New Digital Platform, MyDoc.       » Tapping on ASEAN'S Healthcare Opportunities through Singapore       » ASEAN: The New Playing Field for Global Medical Device Companies       » The Burden of Great Potential: the ASEAN Economic Community & Biopharmaceuticals       » When there is no Queen in the house, Asian Hive Bees Avoid Risky Foraging for Reproduction       » XELJANZTM (Tofacitinib Citrate), A new class of treatment for Rheumatoid Arthritis Approved in Singapore      
BIOBOARD - EYE ON CHINA
QIAGEN launches QuantiFERON-TB gold in-tube in China to aid tuberculosis control
QIAGEN N.V., a leading global provider of Sample & Assay Technologies used to transform biological materials into valuable molecular information commercially launched its QuantiFERON®-TB Gold In-Tube (QuantiFERON-TB), the pioneering blood test that accurately identifies people infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB) in China. QuantiFERON-TB has become the test of choice around the world and is displacing the century-old tuberculin skin test (TST) in screening for TB infection.

China has an estimated 1 million reported new cases of active TB each year, more than any country except India, according to the World Health Organization (WHO). Based on the previous survey, an estimated 550 million people in China, 41% of the population, are infected with the TB bacterium. Globally, WHO estimates one-third of the world's population has latent TB infection. Left untreated 5 to 10% of these people will develop active disease during their lifetimes, often when they experience weakened immunity due to other health issues. With the accelerating urbanization in China, the large population with latent TB infection will potentially increase the incidence of TB disease and transmission of the infection. The incidence of multidrug-resistant TB (MDR-TB) and extreme drug resistance TB (XDR-TB), as well as increased co-morbidities such as human immunodeficiency virus (HIV), diabetes and rheumatoid arthritis, makes TB control more challenging.

In 2012, WHO recommended that an interferon-gamma (IFN-) release assay (IGRA) could be part of clinical evaluation for investigating contacts of persons with infectious tuberculosis in low-and middle-income countries.

QIAGEN's QuantiFERON-TB is the industry-leading IGRA, a modern breakthrough blood test that is faster, more accurate and cost-effective than older methods. QuantiFERON-TB, which measures the body's cell-mediated immune response to a cocktail of TB-specific antigens, is one of the most studied IGRA and commonly used TB-screening assay in industry and clinical research.

"Use of QuantiFERON-TB to screen vulnerable populations is growing rapidly in the United States, Europe and other markets, and we are focusing on this important product as one of QIAGEN's global growth drivers," said Peer Schatz, QIAGEN's Chief Executive Officer. "The superiority of QIAGEN's QuantiFERON technology to deliver more reliable results than the 120-year-old tuberculin skin test already is well accepted among physicians in China, paving the way for the entry of QuantiFERON-TB into this important market."

Source: PR Newswire

Click here for the complete issue.

EDITORS' CHOICE  

Credits to: American Chemical Society
COLUMNS  

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy